The staging of non-small cell lung cancer (NSCLC) provides the anatomical details and the extent of cancer with respect to the size of the primary tumor (T), lymph nodal status (N), and the presence or absence of metastasis (M) in distant organs.\[[@ref1][@ref2]\] The treatment of NSCLC depending on the stage of the disease includes surgical resection with curative intent in early-stage disease and chemoradiation in advanced stage disease.\[[@ref1][@ref2]\] Therefore, an accurate preoperative mediastinal staging is required both to tailor the appropriate treatment and to avoid unnecessary invasive procedures including thoracotomy and surgical resection. One crucial aspect of staging lung cancer is the extent of mediastinal lymph node involvement.

The sampling of mediastinal lymph nodes can be performed using several methods including mediastinoscopy, surgery (open or video-assisted thoracoscopic surgery), endobronchial ultrasound (EBUS)-guided transbronchial needle aspiration (TBNA) with or without endoscopic ultrasound (EUS), or EUS with echobronchoscope (EUS-B)-guided fine needle aspiration (FNA).\[[@ref3][@ref4][@ref5]\] Currently, EBUS-TBNA/EUS/EUS-B-FNA is the preferred modality to sample mediastinal lymph nodes because it is not only minimally invasive but also can be performed under moderate conscious sedation.\[[@ref3][@ref6][@ref7]\]

In general, staging in lung cancer is indicated in those with potentially resectable NSCLC including the following: (i) those who have discrete enlarged mediastinal lymph nodes on computed tomography (CT) of the chest; (ii) those who have high standardized uptake value (SUV)-positive mediastinal lymph nodes on positron emission tomography (PET)-CT; (iii) in large (\>3 cm) central airway tumors; and, (iv) in those with adenocarcinoma with high SUV uptake on PET-CT.\[[@ref8][@ref9]\]

U[TILITY OF]{.smallcaps} EBUS-TBNA/EUS-FNA [IN]{.smallcaps} C[LINICAL]{.smallcaps} S[TAGE]{.smallcaps} N0/N1 NSCLC {#sec1-2}
==================================================================================================================

In subjects with NSCLC, the initial workup for staging is undertaken using radiological methods such as CT thorax and whole-body PET-CT. A radiologically normal mediastinum is defined when the size of lymph nodes on CT thorax is less than 10 mm and there is no uptake on PET-CT. In those with radiologically normal mediastinum or in those with lymph nodes limited to ipsilateral pulmonary and hilar region (N0/N1), surgical resection is the treatment of choice.\[[@ref5][@ref8]\] In clinical N0 disease, the current guidelines do not recommend mediastinal lymph node sampling. However, pathological upstaging (pN2) has been documented in up to 35% of clinical N0 status.\[[@ref10][@ref11]\] The most common lymph node stations that were upstaged were 4R and 7,\[[@ref10]\] which are easily accessible by EBUS-TBNA. This sets up an argument for mediastinal staging in those with the clinical N0/N1 stage. In the preoperative staging of clinical N0/N1 lung cancer, a recent meta-analysis comprising nine studies demonstrated a pooled sensitivity and specificity of 49% \[95% confidence interval (CI), 41%--57%\] and 100% (95% CI, 99%--100%), respectively.\[[@ref12]\] The sensitivity improved to 55% on pooling studies that provided information for lymph nodes accessible for EBUS-TBNA. EBUS-TBNA detected radiologically occult N2/N3 disease in 7.7% (88/1146) of subjects.\[[@ref12]\] The number needed to perform EBUS-TBNA to upstage clinical N0/N1 disease was 14 (95% CI, 11--16). The combined use of EBUS-TBNA/EUS-FNA could further increase the sensitivity of endoluminal ultrasound-guided FNA to 73%. On combining EBUS-TBNA and EUS-FNA, the number of procedures (EBUS/EUS) needed to detect occult N2/N3 disease was 7, which underscores the need for mediastinal lymph node staging even in those with radiologically normal mediastinum.\[[@ref12]\]

U[TILITY OF]{.smallcaps} EBUS-TBNA/EUS-FNA [IN]{.smallcaps} C[LINICAL]{.smallcaps} N2/N3 S[TAGE]{.smallcaps} NSCLC {#sec1-3}
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Compared with the clinical N0/N1 stage where surgical resection is the definitive form of therapy, the treatment in clinical N2/N3 stage lung cancer is either combination chemoradiotherapy or surgery in those with ipsilateral mediastinal lymph node metastases.\[[@ref5][@ref8]\] In a meta-analysis of 11 studies with 1299 subjects who underwent EBUS-TBNA/EUS-FNA for staging before treatment, the pooled sensitivity and specificity of EBUS-TBNA/EUS-FNA to detect mediastinal lymph node metastasis were 93% (95% CI, 91%--94%) and 100% (95% CI, 99%--100%), respectively.\[[@ref13]\] The median prevalence of mediastinal metastases in the studies included in the meta-analysis was 68%.\[[@ref13]\] The pooled sensitivity was 94% in studies where EBUS-TBNA was performed in CT or PET-positive lymph nodes compared with a sensitivity of only 76% where CT or PET status was unknown.\[[@ref13]\] The complication rate of EBUS-TBNA was negligible (0.007%).\[[@ref13]\] However, this meta-analysis included studies with a retrospective study design, and only five studies used surgical specimen as the reference standard.\[[@ref13]\] In another meta-analysis studying the role of EBUS-TBNA in pretreatment mediastinal staging, the combined sensitivity and specificity of EBUS-TBNA for mediastinal staging were 90% (95% CI, 84%--96%) and 99%, respectively.\[[@ref14]\] Only one complication of hypoxia was reported in one study. This meta-analysis included only studies that performed EBUS-TBNA and not EUS-FNA. Thus, in pretreatment mediastinal staging of NSCLC, endosonographic procedures are safe and have a high sensitivity and specificity.

U[TILITY OF]{.smallcaps} EBUS-TBNA/EUS-FNA [IN]{.smallcaps} M[EDIASTINAL]{.smallcaps} R[ESTAGING]{.smallcaps} A[FTER]{.smallcaps} N[EOADJUVANT]{.smallcaps} T[HERAPY]{.smallcaps} {#sec1-4}
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In subjects with stage IIIA/N2 NSCLC, surgical resection with mediastinal lymph node dissection is a preferred modality after successful neoadjuvant therapy.\[[@ref15]\] However, a repeat staging of mediastinum is essential before surgery can be performed as the outcomes following surgery depend on the presence or absence of mediastinal lymph node involvement. Performing surgical restaging after neoadjuvant therapy is challenging as there may be mediastinal fibrosis and adhesions because of either a prior intervention or treatment. Endosonographic procedures could also be used to successfully restage the mediastinal lymph nodes. A recent meta-analysis (10 studies with 574 subjects undergoing mediastinal restaging with EBUS-TBNA/EUS-FNA) demonstrated a pooled sensitivity and specificity of 67% and 99%, respectively.\[[@ref16]\] This suggests that EBUS-TBNA combined with EUS/EUS-B-FNA can be reliably used to restage the mediastinum after neoadjuvant chemotherapy.

U[TILITY OF]{.smallcaps} C[OMBINING]{.smallcaps} EBUS-TBNA [AND]{.smallcaps} EUS/EUS-B-FNA {#sec1-5}
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The specificity of EBUS and EUS in detecting mediastinal nodal metastases is high, but there remains a possibility of missing lymph nodes when either is performed alone. The combination of the two procedures provides a more comprehensive access to the mediastinum. While EBUS-TBNA provides an easy access to lymph nodes in the pretracheal and the paratracheal regions, EUS-FNA is useful for sampling the inferior mediastinum, the left paratracheal region, the left adrenal gland, and occasionally the aortopulmonary lymph node stations.\[[@ref17][@ref18][@ref19]\] Thus, combining both the procedures increases the domain of lymph node stations that can be sampled thereby enhancing the diagnostic yield. EBUS-TBNA and EUS-FNA are performed using a dedicated echobronchoscope and an echoendoscope, respectively. EBUS scope provides access to the mediastinum through the transtracheal route, whereas EUS is used through transesophageal route. Generally, EBUS is performed by a pulmonologist or a thoracic surgeon, whereas EUS is performed by a gastroenterologist. Transesophageal EUS-guided FNA can also be performed using EBUS scope (EUS-B) thus obviating the need for two different types of scopes and operators. A meta-analysis of studies describing the yield of combined EBUS-TBNA and EUS-B-FNA for mediastinal lymph node sampling identified four studies (465 subjects).\[[@ref20]\] The pooled sensitivity of EBUS-TBNA alone was 80% (95% CI, 74%--86%), whereas pooled sensitivity of the combined EBUS-TBNA and EUS-B-FNA was 91% (95% CI, 86%--95%).\[[@ref20]\] The pooled specificity of EBUS-TBNA and the combined procedure (EBUS-TBNA and EUS-B-FNA) was 100%.\[[@ref20]\] The number of combined procedure that needs to be performed to achieve one additional diagnosis was 10 (95% CI, 6--29).\[[@ref20]\] In another recent meta-analysis, 13 studies (*n* = 2395 subjects) were identified that combined both procedures (EBUS and EUS/EUS-B) for mediastinal lymph node staging in NSCLC.\[[@ref21]\] In seven studies, EBUS was done before EUS/EUS-B, and in three studies EUS/EUS-B was performed first.\[[@ref21]\] There were seven and five studies that performed EUS and EUS-B, respectively. The addition of EUS/EUS-B-FNA to EBUS-TBNA increased the sensitivity by 12% (95% CI, 8%--18%). The addition of EBUS-TBNA to EUS/EUS-B-FNA increased the sensitivity by 22% (95% CI, 16%-29%).\[[@ref21]\] The mean sensitivity of the combined approach (EBUS and EUS/EUS-B) was 86% (95% CI, 81%--90%).\[[@ref21]\] The combination of EBUS and EUS/EUS-B procedure also had a good negative predictive value of 0.92 (95% CI, 0.89--0.93).\[[@ref20][@ref21]\] When EBUS and EUS are combined to sample mediastinal lymph nodes, the yield is similar (*P* = 0.056) whether EBUS (82.4%) is performed first or EUS (60%) is performed first.\[[@ref21][@ref22]\] However, nodal upstaging was significantly more when EBUS was performed after EUS.\[[@ref22]\] Importantly, the sensitivity remained similar whether EUS \[85% (95% CI, 78%--90%)\] or EUS-B \[87% (95% CI, 81%--91%)\] was used to access the mediastinum via the esophageal route.\[[@ref21]\] Thus, for a complete mediastinal lymph node assessment, it is best to combine EBUS-TBNA with EUS-B-FNA or EUS-FNA. Additionally, EUS/EUS-B can also be used to sample the left adrenal gland.\[[@ref18]\]

W[HAT]{.smallcaps} I[S THE]{.smallcaps} C[URRENT]{.smallcaps} P[LACE OF]{.smallcaps} M[EDIASTINOSCOPY?]{.smallcaps} {#sec1-6}
===================================================================================================================

Mediastinoscopy has been considered as the reference standard for mediastinal lymph node staging of NSCLC.\[[@ref8][@ref23]\] However, with mediastinoscopy only lymph node stations 2L/2R and 4L/4R can be sampled, whereas stations 10L/10R, 11L/11R, 8, and 9 cannot be sampled.\[[@ref3]\] Also, mediastinoscopy requires general anesthesia and is an invasive procedure. In a recent meta-analysis comprising studies that compared EBUS/EUS procedures head to head with mediastinoscopy, the pooled risk difference of the sensitivity of endosonography versus mediastinoscopy was 0.11 (95% CI, −0.03 to 0.25) suggesting equivalence of the two procedures.\[[@ref3]\] Moreover, the complication rate was significantly lower with endosonographic procedures compared with mediastinoscopy, making EBUS not only equally effective but also a safer method of mediastinal staging of NSCLC.\[[@ref3]\] In those with a negative EBUS-TBNA/EUS-FNA, the current practice is to perform staging mediastinoscopy to rule out false-negatives.\[[@ref24]\] However, a negative EBUS does not always result in a high unforeseen N2 disease at surgical resection.\[[@ref24]\] Furthermore, by omitting mediastinoscopy, there is a possibility to reduce extra waiting time, general anesthesia, and hospitalization. Thus, in patients with a negative EBUS-TBNA, a one approach is to perform surgery directly without waiting for confirmation with a second staging procedure.

In conclusion, endosonographic procedures are the preferred first-line modality for mediastinal lymph node staging in those with clinical stage N0/N1, clinical stage N2/N3, and for mediastinal restaging after neoadjuvant chemotherapy for NSCLC. The endosonography enabled procedures have high sensitivity and specificity both for diagnosing and staging NSCLC. The endosonographic procedures are safe and reproducible. For a complete mediastinal staging, EBUS-TBNA should be combined with EUS-B/EUS-FNA for optimal results.
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